Junxing Shi

1.1k total citations
39 papers, 864 citations indexed

About

Junxing Shi is a scholar working on Infectious Diseases, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Junxing Shi has authored 39 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 17 papers in Molecular Biology and 10 papers in Organic Chemistry. Recurrent topics in Junxing Shi's work include HIV/AIDS drug development and treatment (17 papers), Biochemical and Molecular Research (11 papers) and Hepatitis C virus research (9 papers). Junxing Shi is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), Biochemical and Molecular Research (11 papers) and Hepatitis C virus research (9 papers). Junxing Shi collaborates with scholars based in United States, Switzerland and Canada. Junxing Shi's co-authors include Raymond F. Schinazi, Tamara R. McBrayer, Phillip M. Tharnish, Tony Whitaker, Zbigniew J. Leśnikowski, Chung K. Chu, Lieven Stuyver, Karen S. Anderson, Michaël Otto and Suguna Rachakonda and has published in prestigious journals such as Biochemistry, The FASEB Journal and Journal of Medicinal Chemistry.

In The Last Decade

Junxing Shi

36 papers receiving 832 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junxing Shi United States 16 450 257 244 213 202 39 864
Sylvie Goulet Canada 16 351 0.8× 256 1.0× 290 1.2× 510 2.4× 292 1.4× 20 939
Nghe Nguyen‐Ba Canada 16 600 1.3× 358 1.4× 266 1.1× 297 1.4× 301 1.5× 25 977
Laval Chan Canada 16 384 0.9× 332 1.3× 274 1.1× 427 2.0× 284 1.4× 27 968
Cynthia A. Gates United States 17 343 0.8× 295 1.1× 407 1.7× 437 2.1× 128 0.6× 31 1.2k
John H. Merrett United Kingdom 8 684 1.5× 429 1.7× 252 1.0× 159 0.7× 293 1.5× 10 1.2k
Phillip M. Tharnish United States 17 721 1.6× 460 1.8× 404 1.7× 420 2.0× 373 1.8× 30 1.3k
Blanda Stammen United Kingdom 12 505 1.1× 420 1.6× 195 0.8× 140 0.7× 273 1.4× 15 1.4k
Francesca Curreli United States 19 503 1.1× 431 1.7× 231 0.9× 143 0.7× 222 1.1× 38 1.2k
Bruno Simoneau Canada 18 348 0.8× 338 1.3× 306 1.3× 72 0.3× 485 2.4× 35 1.2k
R. F. SCHINAZI United States 16 670 1.5× 345 1.3× 469 1.9× 316 1.5× 268 1.3× 33 1.3k

Countries citing papers authored by Junxing Shi

Since Specialization
Citations

This map shows the geographic impact of Junxing Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junxing Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junxing Shi more than expected).

Fields of papers citing papers by Junxing Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junxing Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junxing Shi. The network helps show where Junxing Shi may publish in the future.

Co-authorship network of co-authors of Junxing Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Junxing Shi. A scholar is included among the top collaborators of Junxing Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junxing Shi. Junxing Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Amblard, Franck, Sijia Tao, Rana Abdelnabi, et al.. (2025). 1′-Cyanocytidine-5′-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters. Science Advances. 11(40). eadz5913–eadz5913.
2.
Shi, Junxing. (2014). A New Strategy of Drug Delivery: Electric Field Distribution in Brain Tumor Due to Electroporation. Purdue e-Pubs (Purdue University System). 4(1). 58–65. 1 indexed citations
3.
Nettles, James H., Richard A. Stanton, Franck Amblard, et al.. (2014). Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. Journal of Medicinal Chemistry. 57(23). 10031–10043. 35 indexed citations
4.
Amblard, Franck, Hongwang Zhang, Longhu Zhou, et al.. (2013). Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(7). 2031–2034. 21 indexed citations
5.
Shi, Junxing, Anthony Linden, & Heinz Heimgartner. (2013). Reactions of Acid Chlorides/Ketenes with 2‐Substituted 4,5‐Dihydro‐4,4‐dimethyl‐1,3‐thiazoles: Formation of Penam Derivatives. Helvetica Chimica Acta. 96(8). 1462–1481. 5 indexed citations
6.
7.
Shi, Junxing, Longhu Zhou, Franck Amblard, et al.. (2012). Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(10). 3488–3491. 19 indexed citations
8.
Zhang, Hongwang, Longhu Zhou, Franck Amblard, et al.. (2012). Synthesis and evaluation of novel potent HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(14). 4864–4868. 11 indexed citations
9.
Shi, Junxing, Longhu Zhou, Hongwang Zhang, et al.. (2011). Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5′-triphosphates. Bioorganic & Medicinal Chemistry Letters. 21(23). 7094–7098. 16 indexed citations
10.
Safarjalani, Omar N. Al, et al.. (2006). Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. Cancer Chemotherapy and Pharmacology. 58(5). 692–698. 17 indexed citations
11.
Shi, Junxing, Jinfa Du, Tianwei Ma, et al.. (2005). Synthesis and anti-viral activity of a series of d- and l-2′-deoxy-2′-fluororibonucleosides in the subgenomic HCV replicon system. Bioorganic & Medicinal Chemistry. 13(5). 1641–1652. 38 indexed citations
12.
Safarjalani, Omar N. Al, Xiao‐Jian Zhou, Junxing Shi, et al.. (2005). 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemotherapy and Pharmacology. 55(6). 541–551. 55 indexed citations
13.
Du, Jinfa, et al.. (2005). Unusual Olefin Formation by PhSe-Ftrans-Elimination. Nucleosides Nucleotides & Nucleic Acids. 24(9). 1289–1292.
14.
Du, Jinfa, et al.. (2004). Synthesis of 5′- C -methyl-1′,3′-dioxolan-4′-yl nucleosides. Bioorganic & Medicinal Chemistry Letters. 14(5). 1243–1245. 2 indexed citations
15.
Shi, Junxing, Adrian S. Ray, Judy S. Mathew, et al.. (2004). 2 ′ ,3 ′ -Didehydro-2 ′ ,3 ′ -dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. Bioorganic & Medicinal Chemistry Letters. 14(9). 2159–2162. 6 indexed citations
16.
Shi, Junxing, Judy S. Mathew, Phillip M. Tharnish, et al.. (2003). N4-Acyl-Modified D-2′,3′-Dideoxy-5-Fluorocytidine Nucleoside Analogues with Improved Antiviral Activity. Antiviral chemistry & chemotherapy. 14(2). 81–90. 3 indexed citations
17.
Shi, Junxing & Raymond F. Schinazi. (2001). ASYMMETRIC SYNTHESIS OF CARBOCYCLIC PYRIMIDINE NUCLEOSIDES VIA π-ALLYLPALLADIUM COMPLEX. Nucleosides Nucleotides & Nucleic Acids. 20(4-7). 1367–1370. 3 indexed citations
18.
19.
Ma, Li, Selwyn J. Hurwitz, Junxing Shi, et al.. (1999). Pharmacokinetics of the Antiviral Agent β- d -2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine in Rhesus Monkeys. Antimicrobial Agents and Chemotherapy. 43(2). 381–384. 11 indexed citations
20.
Shi, Junxing & Heinz Heimgartner. (1996). New Addition Reactions of Organometal Compounds with 4,4‐Dimethyl‐1,3‐thiazole‐5(4H)‐thiones. Helvetica Chimica Acta. 79(2). 371–384. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvie Goulet Breakdown of academic impact, for papers by Nghe Nguyen‐Ba Breakdown of academic impact, for papers by Laval Chan Breakdown of academic impact, for papers by Cynthia A. Gates Breakdown of academic impact, for papers by John H. Merrett Breakdown of academic impact, for papers by Phillip M. Tharnish Breakdown of academic impact, for papers by Blanda Stammen Breakdown of academic impact, for papers by Francesca Curreli Breakdown of academic impact, for papers by Bruno Simoneau Breakdown of academic impact, for papers by R. F. SCHINAZI
Rankless by CCL
2026